Identification of prognostic factors in patients with diffuse large B-cell lymphoma

被引:5
作者
Peng, Fang [1 ]
Guo, Liang [1 ]
Yao, Wei-Kai [1 ]
Zheng, Yan [1 ]
Liu, Ye [1 ]
Duan, Xiu-Mei [1 ]
Wang, Yin-Ping [1 ]
机构
[1] Jilin Univ, Hosp 1, Dept Pathol, 71 Xinmin St, Changchun, Jilin Province, Peoples R China
关键词
Diffuse large B-cell lymphoma; germinal center B-cell-like subtype; immunophenotyping; international prognostic index; overall survival; prognosis; DLBCL;
D O I
10.4103/0377-4929.200056
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To identify prognostic factors for patients with diffuse large B-cell lymphoma (DLBCL), specifically those classified into conflicting subgroups by Hans' and Choi's classification algorithms. We retrospectively reviewed clinical and pathological data of 154 patients diagnosed with de novo DLBCL in the First Hospital of Jilin University from January 2004 to September 2011. All cases were classified into subgroups based on Hans' and Choi's algorithms with immunohistochemical markers. Statistical Analysis Used: The correlation between various clinicopathological factors and 5-year survival rate, the correlation between those factors with the International Prognostic Index, the concordance between Hans' and Choi's approach was evaluated. The survival in different subtypes as classified by Hans' or Choi's approach was mapped. Results: The Eastern Cooperative Oncology Group (ECOG) performance score 2-5, positive Bcl-2 expression, negative CD10 expression or negative Bcl-6 expression significantly correlated with worse prognosis. The two algorithms showed good consistency (83% concordance, Kappa = 0.660, P < 0.001). By both classifications, the 5-year overall survival rate in germinal center B-cell-like subtype (GCB) lymphoma is significantly higher than that in the non-GCB subtype. There were 25 cases assigned to conflicting subtypes by the two approaches. Among these 25 cases, ECOG 2-5, positive Bcl-2 expression, negative CD10 expression, or negative Bcl-6 expression significantly correlated with worse prognosis. Conclusions: ECOG 2-5, positive Bcl-2 expression, negative CD10 expression, or negative Bcl-6 expression are independent markers for poor prognosis of DLBCL patients. There were 15% cases assigned to conflicting subgroups based on the two algorithms. For these cases, ECOG 2-5, positive Bcl-2 expression, negative CD10 expression, or negative Bcl-6 expression still significantly correlate with poor prognosis.
引用
收藏
页码:87 / 91
页数:5
相关论文
共 12 条
[1]   Roles of BCL6 in normal and transformed germinal center B cells [J].
Basso, Katia ;
Dalla-Favera, Riccardo .
IMMUNOLOGICAL REVIEWS, 2012, 247 :172-183
[2]   CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses [J].
Biasoli, I ;
Morais, JC ;
Scheliga, A ;
Milito, CB ;
Romano, S ;
Land, M ;
Pulcheri, W ;
Spector, N .
HISTOPATHOLOGY, 2005, 46 (03) :328-333
[3]   A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy [J].
Choi, William W. L. ;
Weisenburger, Dennis D. ;
Greiner, Timothy C. ;
Piris, Miguel A. ;
Banham, Alison H. ;
Delabie, Jan ;
Braziel, Rita M. ;
Geng, Huimin ;
Iqbal, Javeed ;
Lenz, Georg ;
Vose, Julie M. ;
Hans, Christine P. ;
Fu, Kai ;
Smith, Lynette M. ;
Li, Min ;
Liu, Zhongfeng ;
Gascoyne, Randy D. ;
Rosenwald, Andreas ;
Ott, German ;
Rimsza, Lisa M. ;
Campo, Elias ;
Jaffe, Elaine S. ;
Jaye, David L. ;
Staudt, Louis M. ;
Chan, Wing C. .
CLINICAL CANCER RESEARCH, 2009, 15 (17) :5494-5502
[4]   Diffuse large B-cell lymphoma - Molecular heterogeneity of diffuse large B-cell lymphoma [J].
Gascoyne, RD .
HEMATOLOGY JOURNAL, 2004, 5 :S144-S148
[5]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282
[6]   Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL) [J].
Markovic, Olivera ;
Marisavljevic, Dragomir ;
Cemerikic, Vesna ;
Perunicic, Maja ;
Savic, Sasa ;
Filipovic, Branka ;
Mihaljevic, Biljana .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (03) :246-255
[7]   Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) [J].
Mounier, N ;
Briere, J ;
Gisselbrecht, C ;
Emile, JF ;
Lederlin, P ;
Sebban, C ;
Berger, F ;
Bosly, A ;
Morel, P ;
Tilly, H ;
Bouabdallah, R ;
Reyes, F ;
Gaulard, P ;
Coiffier, B .
BLOOD, 2003, 101 (11) :4279-4284
[8]  
Sabatini E, 2010, PATHOLOGICA, V102, P83
[9]   Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning [J].
Shipp, MA ;
Ross, KN ;
Tamayo, P ;
Weng, AP ;
Kutok, JL ;
Aguiar, RCT ;
Gaasenbeek, M ;
Angelo, M ;
Reich, M ;
Pinkus, GS ;
Ray, TS ;
Koval, MA ;
Last, KW ;
Norton, A ;
Lister, TA ;
Mesirov, J ;
Neuberg, DS ;
Lander, ES ;
Aster, JC ;
Golub, TR .
NATURE MEDICINE, 2002, 8 (01) :68-74
[10]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994